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 Abstract: 
 
Although the hot flush is generally recognised by women and the medical profession 
as the most characteristic and often a very distressing symptom of the climacteric, it 
remains an enigma. The physiological changes associated with the hot flush are 
different from any other flushing condition, with an increased peripheral blood flow, 
increased heart rate and in particular a decrease in galvanic skin resistance, which is 
unique to the flush. Flushing occurs as a result of disturbance of the temperature 
regulating mechanism situated in the hypothalamus, and probably a reduction in the 
thermoneutral zone, within which fluctuations of basal body temperature do not 
provoke compensatory vascular responses. Many factors have been implicated, 
including hormone releasing factors, gonadotrophins and neuro-humorals.  However, 
the role of oestrogen is critical and the clinical value of oestrogen therapy is well 
established and has been confirmed by a Cochrane review.  Nevertheless, the precise 
mechanism by which reduced circulating levels of oestrogen are involved in causing 
the flush has not yet been established.   
Priming with oestrogen seems to be an essential pre-requisite for flushing, as young 
women with ovarian dysgenesis and very low circulating levels of oestrogen never 
have hot flushes unless they are given oestrogen replacement therapy, which is later 
discontinued.  Oestrogen antagonist activity by selective oestrogen receptor 
modulators such as tamoxifen and raloxifene can also cause flushing.  A link with 
gonadotrophins is demonstrated by a temporal association of flushes with the pulsatile 
release of luteinising hormone (LH).  However, if LH pulses are eliminated by GnRH 
analogue, the frequency of flushing is not altered, which confirms that LH is merely 
associated with the flush rather than being causative.  
 It is probable that the flush is initiated by a supra-pituitary mechanism which is 
influenced by the hypothalamic factors responsible for pulsatile LH release.  A variety 
of chemical pathways have been proposed involving serotonin, noradrenalin and 
dopamine.  Trials of drugs that selectively inhibit the re-uptake of serotonin and 
noradrenalin have shown some beneficial effects, as also has gabapentin, but often the 
results have been disappointing, and certainly less than the response seen with 
oestrogen or tibolone.  
 The prevalence of hot flushes varies considerably around the world and is less in the 
Far East than in the west.  Differences in diet and in particular the intake of 
phytoestrogens has been implicated and many studies have tried to establish whether 
dietary supplementation with phytoestrogens might be a suitable alternative to 
conventional hormone replacement therapy(HRT).  So far, the results are 
disappointing. Other lifestyle measures such as avoiding  alcohol, caffeine and spicy 
foods, keeping the core body temperature cool, paced respiration, taking exercise and 
even acupuncture may help. 
Hot flushes remain a major cause of reduced quality of life in a large proportion of 
menopausal women, but perhaps because they are not fatal and are usually self-
limiting, there has been rather limited research or clinical interest.  However, for the 
increasing number of women being treated with tamoxifen for breast cancer, and for 
whom oestrogen will usually be contra-indicated or unsuitable, there is an urgent need 
to identify the underlying mechanism so that appropriate, specific and safe non-
oestrogen therapy can be offered to improve their quality of life. 
 
 
Introduction 
 
The hot flush associated with the menopause is a unique symptom and causes 
considerable distress and impairment of quality of life.  Although flushing occurs in 
some other conditions such as carcinoid syndrome, phaeochromocytoma, thyroid 
disease and the dumping syndrome, the associated physiological changes are not the 
same.   
 
Around the world there is a considerable variation in prevalence ranging from 80% in 
Dutch women
 
[1] to 0% among rural Mayan Indians in Mexico [2,3].  While 
differences in study design may account for some of this disparity in reported 
prevalence rates, there are also cultural and ethnic differences to consider.  Rumours 
that Japanese women rarely experienced flushes due to their life-long high intake of 
soy products in their diet have not been supported by recent evidence [3-5]. In North 
America, African American women experience more troublesome vasomotor 
symptoms than white women [6].  Race-ethnicity-specific associations between 
vasomotor symptom reporting and specific polymorphisms for sex steroid 
metabolising enzymes and sex steroid receptors have also been reported [7].  It has 
been considered that women who are overweight are less likely to experience hot 
flushes due to peripheral conversion of androgens in the adipose tissue to oestrone.  
However, recent analysis from the Study of Women’s Health Across the Nation 
(SWAN) has shown that a higher percentage of body fat is associated with an 
increased likelihood of reporting vasomotor symptoms [8], possibly due to more body 
insulation thereby maintaining a higher core body temperature. 
Climate may be an important factor affecting the frequency of flushing. A meta-
analysis of 54 studies demonstrated that, although climate plays a role in the variation 
of the prevalence of hot flushes, the incidence was not associated with mean 
temperature of the warmest month. The frequency appears to increase as the 
difference in temperatures between the hottest and coldest months increase. So 
women living in seasonal climates may have greater sensitivity to temperature 
changes [9].  
 
Subjective Features 
 
Hot flushes may occur at any time of the day or night and be triggered by a variety of 
common situations but in particular embarrassment, stress, sudden temperature 
change, alcohol, caffeine or any warm drink.  These subjective features are variable 
but usually start with a sudden sensation of heat or warmth, often accompanied by 
sweating and reddening of the skin and sometimes palpitations.  Most often this will 
start in the upper body or back and spread upwards or downwards, and sometimes all 
over the body.  The perceived duration of a flush ranges from 30 seconds to 60 
minutes with a mean between 3-4 minutes [10,11].  Prodromal symptoms are common 
and for many include a feeling of “increasing pressure in the head”, though most 
women have difficulty in describing this sensation [12].  During the night a decrease 
of rapid eye movement (REM) sleep and waking often precedes a hot flush [13,14]. 
The frequency of flushes varies between individuals ranging from a few per month to 
several per hour.  For clinical studies of the effect of treatments for hot flushes, 
regulatory authorities require the patients to have at least 50 hot flushes a week.  For 
most women the hot flushes will continue for more than one year, and for about 25% 
for more than 5 years.  Occasionally women will still be experiencing flushes for up 
to 40 years [15].  
 
The impact of hot flushes on the quality of life may be considerable and is probably 
often underestimated.  Flushing interferes with work and daily activities as well as 
with sleep causing subsequent fatigue, loss of concentration, depression and all of this 
can interfere with family life as well as sexual function and partner relationships.   
 
 
 
 
 
 
Physiological Changes 
 
The subjective sensation of heat is the predominant feature of the flush.  Temperature 
changes occur over a large portion of the body [16] and can be demonstrated by 
thermography [17] with temperature increases in the fingers and toes from about 20 to 
33ºC  [16,18,19].  As a result of the rise in peripheral body temperature there is a 
concomitant decrease in core temperature as recorded in the rectum and tympanic 
membrane [16]. Although the greatest temperature changes have been found in the 
fingers and toes, the symptom of flushing is usually experienced mainly in the face, 
neck and upper trunk, and it seems that the subjective sensation of heat is out of 
proportion to the actual temperature increase, which in these areas may be only about 
1ºC [17].  Furthermore, the temperature increase often persists for several minutes 
after the sensation of warmth has passed, indicating that the flush is only experienced 
while the skin temperature is increasing.  The severity of the sensation is therefore 
probably related more to the rate of temperature change than to actual temperature 
increase. 
 
The increase in skin temperature results from a sudden peripheral vasodilatation, 
which has been demonstrated by plethysmography in the fingers, hands or arms 
[19,20].  See Fig. 1.  This increased blood flow precedes the subjective sensation of 
the flush by at least one minute and persists for many minutes afterwards declining 
gradually along with the temperature.  A rise in the heart rate, however, coincides 
with the sensation of flushing and usually returns to normal almost as quickly.  Some 
women complain of palpitations before or during a flush, but no changes in cardiac 
rhythm have been found in flushing women who have had continuous 24 hour 
electrocardiograph (ECG) recordings [11].  However, fluctuation of the ECG baseline 
as shown in Fig. 1 has been a consistent finding at the onset of peripheral 
vasodilatation, and is probably due to a change in galvanic skin resistance as well as 
some sweating under the electrodes.  A rapid and prolonged fall in skin resistance is 
also a characteristic feature and may be the first objective sign of an impending flush.  
Measurement of the skin resistance is probably the most reliable way of 
distinguishing a hot flush from other causes of peripheral vasodilatation [21], and for 
this purpose instruments are being designed to aid in the study of this condition [22].   
 
 Mechanism of Hot Flush 
 
The hot flush is not easy to study.  The human female is almost unique in 
experiencing this symptom, but animal models using monkeys and rats in which a 
surgical menopause has been induced, have provided some information [23], although 
how much this can be extrapolated to the human female is uncertain.  The flush 
occurs as a result of a disturbance of the temperature regulating mechanism, which is 
situated in the hypothalamus.  Many possible factors have been implicated including 
pituitary hormones, hormone releasing factors, gonadotrophins and neurohumoral 
pathways.  A hormonal aetiology seems likely in view of the association of flushing 
with the climacteric, and the well-proven clinical value of oestrogen therapy in 
eliminating hot flushes [24], but the precise role that oestrogens play has yet to be 
established.  A most attractive explanation of the mechanism at present is that from 
Robert Freedman [25], who has been one of very few recent investigators of the flush. 
See Fig.2.  In the normal and asymptomatic woman there is a thermoneutral zone 
(about 0.4ºC), within which fluctuations of the core body temperature do not trigger 
compensatory mechanisms such as flushing or sweating.  In the symptomatic woman 
the thermoneutral zone is considerably reduced, so that even minor fluctuations in 
core body temperature will reach the limits of the zone, and initiate a 
thermoregulatory response.  The narrowing of the zone may be due to elevated central 
noradrenergic activation and probably precipitated by changes in oestrogen.  
 
The association of flushing with the decline in oestrogen around the menopause is not 
clearly understood and indeed there are many situations that seem inconsistent with an 
oestrogen deficiency aetiology.  Pre-pubertal girls have low circulating oestrogen 
levels but do not experience hot flushes, whereas they may occur in pregnancy when 
there is a high level of oestrogen production.  Many women will pass through the 
climacteric without experiencing any hot flushes and there is no apparent difference in 
the oestrogen levels of these women compared with those who do flush [26,27].  
Flushes are more prevalent in women who experience acute oestrogen withdrawal, 
such as following bilateral oophorectomy, than in those experiencing the gradual 
ovarian failure of a physiological climacteric.  In addition, hot flushes are often the 
first symptom of the climacteric and do not usually persist in to the later 
postmenopause years when circulating oestrogen levels are very low.   
 
Priming with oestrogen may be an essential pre-requisite for flushing, as young 
women with ovarian dysgenesis do not have hot flushes unless they are given 
oestrogen replacement therapy, which is later discontinued.  Furthermore, infertile 
women taking clomiphene therapy may also complain of flushes, perhaps due to the 
anti-estrogenic action of the drug at the hypothalamus.   
 
Gonadotrophins 
 
Both primary and secondary ovarian failure are associated with elevated secretion of 
follicle stimulating hormone (FSH) and luteinising hormone (LH), but only women 
with secondary amenorrhoea experience flushing.  Gonadotrophin therapy given to 
infertile women does not provoke hot flushes and conversely flushes have been 
reported in women with pituitary insufficiency [28].  Although there is no difference 
in overall levels of FSH and LH between postmenopausal women who flush and those 
who do not, a temporal association of flushes with the pulsatile pituitary release of LH 
has been demonstrated [29]. However, further studies in which the LH pulses were 
eliminated by an LHRH analogue without affecting the frequency of flushing 
episodes, confirm that LH is merely associated with the flush rather than being 
causative [30].  It is possible that neuroendocrine events in the hypothalamus which 
govern the pulsatile release of LHRH may be linked functionally with 
thermoregulation, as some of the hypothalamic neurones that contain LHRH are 
closely related, anatomically at least, to the pre-optic anterior nuclei that regulate 
body temperature [31].   
 
Serotonin 
 
In recent years there has been increasing interest in the potential role of serotonin or  
5-hydroxytriptomine (5-HT) in the mechanism of flushing.  Serotonin is involved in 
many functions including mood, anxiety, memory, sleep, sexual and eating behaviour, 
and after the menopause the blood levels decrease by about 50% and oestrogen 
therapy restores these levels. There are multiple serotonin binding sites and at least  
three different types.  Activation of 5-HT 1α causes hypothermia and activation of  
5-HT 2α causes hyperthermia [32]. The interaction of oestrogen 5-HT and other 
neurotransmitters may be explained by the following sequence of events: 
 Oestrogen enhances the synthesis of 5-HT and endorphins.   
 Endorphins and 5-HT inhibit the production of noradrenalin.   
 The withdrawal of oestrogen in the climacteric is associated with decreasing 
levels of endorphin and 5-HT and an increase in 5-HT receptors. 
 This results in a loss of the feedback mechanism of noradrenalin production 
causing an increase in noradrenalin, which may reduce the thermoneutral 
zone and thereby increase the likelihood of flushing.   
 Therefore any substance that increases 5-HT, oestrogen, endorphins or 
decreases noradrenalin may widen the thermoneutral zone and therefore be 
expected to reduce hot flushes.  
 
 The effectiveness of several selective serotonin re-uptake inhibitors (SSRI) agents 
in the treatment of hot flushes has been studied with paroxetine and venlafaxine 
showing the most promise. However, they do not suppress flushes as well as 
oestrogen and the side effects may limit their acceptability [33].  Most studies were 
in women treated for breast cancer and more long-term data are required from 
healthy women.  
The anticonvulsant gabapentin has been studied in randomised placebo controlled 
trials and has even been shown to have a similar effect to conjugated equine 
oestrogens in one small study [34].  However, the mechanism of action is unknown 
and side effects are quite common [33,35].   
 
 
Alternative therapies 
 
With the widespread alarm about the supposed risks of hormone replacement therapy 
(HRT) induced by the media in particular, the atmosphere has been ripe for promotion 
of alternative therapies and complimentary medicines, which claim that because they 
are not HRT they must be safer.  Phyto-oestrogens are substances produced from 
plants with weak estrogenic and anti-estrogenic activity.  Red clover isoflavones have 
been the subject of several trials of which five out of six randomised controlled trials 
showed no improvement in hot flushes [33].  Soy Isoflavones have also shown mixed 
results with most trials showing no improvement in hot flushes and gastrointestinal 
side effects are common.  However, they may induce endometrial hyperplasia [36], 
which does indicate some estrogenic activity.  Black cohosh does not seem to 
demonstrate any significant benefit over placebo, and in one study the patients 
preferred placebo to Black cohosh [37].  Furthermore, the possible mechanism of 
action of Black cohosh is largely unknown although there may be some binding to 
oestrogen receptors, there is a wide variation between and within products and there 
have now been several reports of liver failure requiring transplantation and other 
disturbance of liver function [38,39].  Many of these preparations are promoted as 
being “natural” with the evidently false assumption that this implies absence of risk 
[40]. 
 Women treated with acupuncture have reported a reduction of more than 50% in their 
hot flushes, but most studies are of poor quality with an inadequate control method. 
There is certainly a need for a large double-blind, randomized, controlled trial 
comparing acupuncture with HRT and a credible placebo acupuncture in order to 
provide reliable evidence [41].   
An alternative licensed medication, which has been available for many years is 
Clonidine.  This is an alpha-adrenergic agonist that may reduce peripheral vascular 
reactivity.  Around half of the several randomised controlled trials have shown a 
reduction in the frequency and severity of hot flushes by between 1 and 2 hot flushes 
per day [33,40], but side effects such as dry mouth, visual disturbance, drowsiness 
and insomnia are quite common.   
In all studies of the treatment of hot flushes, the placebo response is powerful and 
significant and in a Cochrane analysis of HRT trials it ranged from 31-59%, one of 
the highest for any medication [24,42]. Thus any alternative therapy must be properly 
measured against a placebo in an appropriately designed randomized trial [43]. 
None of the alternatives are as effective as oestrogen or tibolone, and few have been 
studied beyond a few weeks, so that whatever efficacy they may have, is unknown in 
the long term as well as their safety [40,44].  
 
Lower dose HRT and progestogens 
 
 Regulatory authorities are recommending the use of the lowest effective dose of 
hormone therapy regimens and for the shortest duration. Recent studies have 
demonstrated that doses as low as conjugated equine oestrogens 0.3mg daily [44], oral 
oestradiol 0.5mg [45] and transdermal oestradiol 14µg daily [46] can be significantly 
more effective than a placebo, and when combined with a progestogen the effects 
seem to be even greater.   
Progestogens alone, such as norethisterone [48], megestrol [49] and 
medroxyprogesterone acetate [50] have also been shown to reduce flushes, though 
their potential for causing adverse events has to be considered [44]. 
Life-style measures 
 
For women with mild hot flushes, simple life-style measures such as keeping the core 
body temperature cool, avoiding alcohol, caffeine and spicy foods, taking regular 
exercise and using paced respiration [51] may be sufficient to reduce the severity and 
frequency of flushing satisfactorily. But, severe and frequent flushes that significantly 
impair quality of life will need specific treatment for which conventional HRT is by 
far the most potent. Following the early reports from the Women’s Health Initiative 
and the exaggerated scares about HRT in the media,  women are being falsely 
informed that ‘Bioidentical hormone therapy (BHT) has all of the good effects of 
HRT with none of the severe side-effects that have caused so many women to avoid 
traditionally administered HRT’. In addition it is suggested that the dose of these 
hormones can be tailored to the individual based on measurement of salivary hormone 
levels. None of these claims are supported by scientific evidence such that The 
Endocrine Society [52], the International Menopause Society [53] and the U.S. Food 
and Drug Administration (FDA) [54] have all condemned this false advertising and 
cautioned women and their physicians about using BHT.   
 
 
Terminology 
 
It is important to have uniformity of scientific terminology, and the use of the term 
flash instead of flush by North American colleagues is both regrettable and 
inappropriate. The Concise Oxford Dictionary states that flash implies a sudden 
transitory blaze, whereas a flush implies a prolonged suffusion with a warm colour 
rather than a transient event. It is unlikely that this habit will change but any woman 
experiencing flushes will confirm that it is rarely over in a flash. 
 
Discussion 
 
Although the hot flush is the most characteristic and recognised feature of the 
climacteric, it is still poorly understood and the causative mechanism not yet 
established. It is a major cause of reduced quality of life for most women passing 
through this phase of their life and it is most regrettable that with the inappropriate 
reporting of the results of the WHI studies in particular, that so many women around 
the world have been denied the opportunity of easy and safe relief from these 
symptoms. In addition, there are many women suffering from flushes resulting from 
their treatment for breast cancer, for whom HRT will usually be considered 
inappropriate. It is for these women and others who are unable to take oestrogen, that 
suitable non-hormonal alternative therapies are urgently needed. For this we need to 
identify the underlying mechanism of flushing and more research in this area is 
required.  
So there is not much new on this subject. The flush was studied much more in the 
1970-80’s than in recent years and the pace of research seems to have slowed, perhaps 
because it is a benign and self limiting symptom, but it is unique and remains the 
enigma of the menopause. 
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Figures 
 
 
 
 
 
 
 
Figure 1: Physiological changes during a hot flush. 
a)  Heart rate. 
b)  Digital plethysmograph demonstrating the change in blood flow 
associated with a flush. 
c) Single lead chest electrocardiograph record. 
[From reference 20 with permission] 
 
 
 
 
 
